Hoth Therapeutics (HOTH) and Silo Pharma (SILO) announced the formation of a joint venture to develop and commercialize a treatment for obesity and metabolic disease based on technology licensed from the U.S. Department of Veterans Affairs. The therapeutic platform centers on Glial Cell Line-Derived Neurotrophic Factor, a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models.
"With obesity at epidemic levels and no curative therapies available, we believe GDNF is a game-changer," said Eric Weisblum, CEO of Silo Pharma.
Shares of Hoth Therapeutics are up 3% in pre-market trade on Wednesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.